Drugs / ALZT-OP1b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02482324 | Jun → Jul 2015 | — | AZTherapies, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02547818 Comparator | Sep 2015 → Nov 2020 | Alzheimer disease | AZTherapies, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALZT-OP1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02482324 ↗ |
| Route | Oral | “single oral tablet dose of ALZT-OP1b” NCT02482324 ↗ |